Changes in mucosa‑associated lymphoid tissue 1 predicts therapeutic response and survival in patients with advanced melanoma receiving programmed cell death‑1 inhibitor monotherapy

Miao,Xiaoyan; Guo,Ziyi; Zhang,Kai; Chang,Jin; Yang,Jianmin; Miao,Guoying; Tian,Yan

doi:10.3892/ol.2024.14566

Changes in mucosa‑associated lymphoid tissue 1 predicts therapeutic response and survival in patients with advanced melanoma receiving programmed cell death‑1 inhibitor monotherapy

Authors:
- Xiaoyan Miao
- Ziyi Guo
- Kai Zhang
- Jin Chang
- Jianmin Yang
- Guoying Miao
- Yan Tian
View Affiliations

Affiliations: Department of Plastic Surgery, Affiliated Hospital of Hebei Engineering University, Handan, Hebei 056002, P.R. China, Department of Burn and Plastic Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China, Department of Orthopedics 1, Handan Central Hospital, Handan, Hebei 056000, P.R. China, Department of Plastic Surgery, Beijing Tsinghua Changgung Hospital, Beijing 102218, P.R. China, Department of Dermatology, Affiliated Hospital of Hebei Engineering University, Handan, Hebei 056002, P.R. China
Published online on: July 12, 2024 https://doi.org/10.3892/ol.2024.14566
Article Number: 433
Copyright: © Miao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Advanced melanoma is an aggressive and dangerous form of skin cancer, and programmed cell death‑1 (PD‑1) inhibitors are recommended treatment options for patients with advanced melanoma. Mucosa‑associated lymphoid tissue 1 (MALT1) impairs CD8⁺ T‑cell activation to induce immune escape, leading to a reduction in the antitumor effect of PD‑1 inhibitors. The present study aimed to assess the prognostic implication of MALT1 in patients with advanced melanoma receiving PD‑1 inhibitor monotherapy. Blood MALT1 levels were assessed using reverse transcription‑quantitative PCR in 20 healthy controls (HCs) after enrollment and in 49 patients with advanced melanoma before (T₀), as well as 2 months (T₁) and 4 months after (T₂) PD‑1 inhibitor monotherapy. The maximum level of MALT1 in HCs (3.100) was used as the cut‑off in patients with advanced melanoma. MALT1 levels at T₀ were significantly increased in patients with advanced melanoma compared with in HCs (P<0.001). In patients with advanced melanoma, MALT1 was significantly decreased from T₀ to T₂ (P<0.001). Objective response rate (ORR) and disease control rate (DCR) were 28.6 and 59.2%, respectively. MALT1 levels at T₁ were significantly negatively associated with overall therapeutic response (P=0.001), ORR (P=0.009) and DCR (P=0.004). MALT1 levels at T₂ were significantly inversely associated with overall therapeutic response (P=0.021) and ORR (P=0.036). Moreover, MALT1 levels >3.100 at T₀ (P=0.027) and T₁ (P=0.045) were significantly associated with shorter progression‑free survival (PFS), and MALT1 levels >3.100 at T₁ were significantly associated with a poor overall survival (OS; P=0.022). Multivariate Cox regression analysis demonstrated that MALT1 levels at T0 (>3.100 vs. ≤3.100) were significantly associated with a poor PFS [hazard ratio (HR)=2.248; P=0.037], and MALT1 levels at T1 (>3.100 vs. ≤3.100) were significantly associated with a poor OS (HR=4.332; P=0.007). In conclusion, MALT1 levels are reduced following PD‑1 treatment, and a high MALT1 level is associated with a poor therapeutic response and shorter survival in patients with advanced melanoma receiving PD‑1 inhibitor monotherapy.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A and Ugurel S: Melanoma. Lancet. 392:971–984. 2018. View Article : Google Scholar : PubMed/NCBI
3	Teixido C, Castillo P, Martinez-Vila C, Arance A and Alos L: Molecular markers and targets in melanoma. Cells. 10:23202021. View Article : Google Scholar : PubMed/NCBI
4	Shreberk-Hassidim R, Ostrowski SM and Fisher DE: The complex interplay between nevi and melanoma: Risk factors and precursors. Int J Mol Sci. 24:35412023. View Article : Google Scholar : PubMed/NCBI
5	Serman N, Vranic S, Glibo M, Serman L and Bukvic Mokos Z: Genetic risk factors in melanoma etiopathogenesis and the role of genetic counseling: A concise review. Bosn J Basic Med Sci. 22:673–682. 2022.PubMed/NCBI
6	Raimondi S, Suppa M and Gandini S: Melanoma epidemio-logy and sun exposure. Acta Derm Venereol. 100:adv001362020. View Article : Google Scholar : PubMed/NCBI
7	Majem M, Manzano JL, Marquez-Rodas I, Mujika K, Muñoz-Couselo E, Pérez-Ruiz E, de la Cruz-Merino L, Espinosa E, Gonzalez-Cao M and Berrocal A: SEOM clinical guideline for the management of cutaneous melanoma (2020). Clin Transl Oncol. 23:948–960. 2021. View Article : Google Scholar : PubMed/NCBI
8	Villani A, Potestio L, Fabbrocini G, Troncone G, Malapelle U and Scalvenzi M: The treatment of advanced melanoma: Therapeutic update. Int J Mol Sci. 23:63882022. View Article : Google Scholar : PubMed/NCBI
9	Curti BD and Faries MB: Recent advances in the treatment of melanoma. N Engl J Med. 384:2229–2240. 2021. View Article : Google Scholar : PubMed/NCBI
10	Santamaria-Barria JA and Mammen JMV: Surgical management of melanoma: Advances and updates. Curr Oncol Rep. 24:1425–1432. 2022. View Article : Google Scholar : PubMed/NCBI
11	Wollina U: Melanoma surgery-An update. Dermatol Ther. 35:e159662022. View Article : Google Scholar : PubMed/NCBI
12	Jenkins RW and Fisher DE: Treatment of advanced melanoma in 2020 and beyond. J Invest Dermatol. 141:23–31. 2021. View Article : Google Scholar : PubMed/NCBI
13	Huang AC and Zappasodi R: A decade of checkpoint blockade immunotherapy in melanoma: Understanding the molecular basis for immune sensitivity and resistance. Nat Immunol. 23:660–670. 2022. View Article : Google Scholar : PubMed/NCBI
14	Fujimura T, Muto Y and Asano Y: Immunotherapy for melanoma: The significance of immune checkpoint inhibitors for the treatment of advanced melanoma. Int J Mol Sci. 23:157202022. View Article : Google Scholar : PubMed/NCBI
15	Sabbatino F, Liguori L, Pepe S and Ferrone S: Immune checkpoint inhibitors for the treatment of melanoma. Expert Opin Biol Ther. 22:563–576. 2022. View Article : Google Scholar : PubMed/NCBI
16	Carlino MS, Larkin J and Long GV: Immune checkpoint inhibitors in melanoma. Lancet. 398:1002–1014. 2021. View Article : Google Scholar : PubMed/NCBI
17	Eddy K and Chen S: Overcoming immune evasion in melanoma. Int J Mol Sci. 21:89842020. View Article : Google Scholar : PubMed/NCBI
18	Brown LJ, da Silva IP, Moujaber T, Gao B, Hui R, Gurney H, Carlino M and Nagrial A: Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune check-point inhibitors in Australian tertiary oncology centres. Cancer Med. 12:6788–6801. 2023. View Article : Google Scholar : PubMed/NCBI
19	Zaremba A, Eggermont AMM, Robert C, Dummer R, Ugurel S, Livingstone E, Ascierto PA, Long GV, Schadendorf D and Zimmer L: The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients. Eur J Cancer. 155:268–280. 2021. View Article : Google Scholar : PubMed/NCBI
20	O'Neill TJ, Tofaute MJ and Krappmann D: Function and targeting of MALT1 paracaspase in cancer. Cancer Treat Rev. 117:1025682023. View Article : Google Scholar : PubMed/NCBI
21	Yang N, Ji F, Cheng L, Lu J, Sun X, Lin X and Lan X: Knockout of immunotherapy prognostic marker genes eliminates the effect of the anti-PD-1 treatment. NPJ Precis Oncol. 5:372021. View Article : Google Scholar : PubMed/NCBI
22	Rosenbaum M, Gewies A, Pechloff K, Heuser C, Engleitner T, Gehring T, Hartjes L, Krebs S, Krappmann D, Kriegsmann M, et al: Bcl10-controlled Malt1 paracaspase activity is key for the immune suppressive function of regulatory T cells. Nat Commun. 10:23522019. View Article : Google Scholar : PubMed/NCBI
23	Cheng L, Deng N, Yang N, Zhao X and Lin X: Malt1 protease is critical in maintaining function of regulatory T cells and may be a therapeutic target for antitumor immunity. J Immunol. 202:3008–3019. 2019. View Article : Google Scholar : PubMed/NCBI
24	Azam F, Latif MF, Farooq A, Tirmazy SH, AlShahrani S, Bashir S and Bukhari N: Performance status assessment by using ECOG (eastern cooperative oncology group) score for cancer patients by oncology healthcare professionals. Case Rep Oncol. 12:728–736. 2019. View Article : Google Scholar : PubMed/NCBI
25	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
27	Wang Q, Wang Y, Liu Q, Chu Y, Mi R, Jiang F, Zhao J, Hu K, Luo R, Feng Y, et al: MALT1 regulates Th2 and Th17 differentiation via NF-κB and JNK pathways, as well as correlates with disease activity and treatment outcome in rheumatoid arthritis. Front Immunol. 13:9138302022. View Article : Google Scholar : PubMed/NCBI
28	Song C, Liu X, Lin W, Lai K, Pan S, Lu Z, Li D, Li N and Geng Q: Systematic analysis of histone acetylation regulators across human cancers. BMC Cancer. 23:7332023. View Article : Google Scholar : PubMed/NCBI
29	Qian R, Niu X, Wang Y, Guo Z, Deng X, Ding Z, Zhou M and Deng H: Targeting MALT1 suppresses the malignant progression of colorectal cancer via miR-375/miR-365a-3p/NF-κB axis. Front Cell Dev Biol. 10:8450482022. View Article : Google Scholar : PubMed/NCBI
30	Kurden-Pekmezci A, Cakiroglu E, Eris S, Mazi FA, Coskun-Deniz OS, Dalgic E, Oz O and Senturk S: MALT1 paracaspase is overexpressed in hepatocellular carcinoma and promotes cancer cell survival and growth. Life Sci. 323:1216902023. View Article : Google Scholar : PubMed/NCBI
31	Tsui KH, Chang KS, Sung HC, Hsu SY, Lin YH, Hou CP, Yang PS, Chen CL, Feng TH and Juang HH: Mucosa-associated lymphoid tissue 1 is an oncogene inducing cell proliferation, invasion, and tumor growth via the upregulation of NF-κB activity in human prostate carcinoma cells. Biomedicines. 9:2502021. View Article : Google Scholar : PubMed/NCBI
32	Li C, Yu F and Xu W: Early low blood MALT1 expression levels forecast better efficacy of PD-1 inhibitor-based treatment in patients with metastatic colorectal cancer. Oncol Lett. 26:3292023. View Article : Google Scholar : PubMed/NCBI
33	Wang Y, Zhang G, Jin J, Degan S, Tameze Y and Zhang JY: MALT1 promotes melanoma progression through JNK/c-Jun signaling. Oncogenesis. 6:e3652017. View Article : Google Scholar : PubMed/NCBI
34	Moreira RS, Bicker J, Musicco F, Persichetti A and Pereira AMPT: Anti-PD-1 immunotherapy in advanced metastatic melanoma: State of the art and future challenges. Life Sci. 240:1170932020. View Article : Google Scholar : PubMed/NCBI
35	Luke JJ, Flaherty KT, Ribas A and Long GV: Targeted agents and immunotherapies: Optimizing outcomes in melanoma. Nat Rev Clin Oncol. 14:463–482. 2017. View Article : Google Scholar : PubMed/NCBI
36	Di Pilato M, Kim EY, Cadilha BL, Prüßmann JN, Nasrallah MN, Seruggia D, Usmani SM, Misale S, Zappulli V, Carrizosa E, et al: Targeting the CBM complex causes T_reg cells to prime tumours for immune checkpoint therapy. Nature. 570:112–116. 2019. View Article : Google Scholar : PubMed/NCBI